Overview Dividends

(RCKT) Rocket Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US77313F1066

Gene, Therapy, Cardiomyopathy, Anemia, Immunodeficiency

RCKT EPS (Earnings per Share)

EPS (Earnings per Share) of RCKT over the last years for every Quarter: "2020-09": -0.53, "2020-12": -1.08, "2021-03": -0.65, "2021-06": -0.55, "2021-09": -0.79, "2021-12": -0.69, "2022-03": -0.67, "2022-06": -0.83, "2022-09": -0.87, "2022-12": -0.92, "2023-03": -0.73, "2023-06": -0.82, "2023-09": -0.75, "2023-12": -0.64, "2024-03": -0.66, "2024-06": -0.74, "2024-09": -0.71, "2024-12": -0.62, "2025-03": -0.56, "2025-06": -0.62, "2025-09": 0,
EPS Growth (3Y CAGR): 163.97%
EPS Trend (3Y Correlation): 71.8%

RCKT Revenue

Revenue of RCKT over the last years for every Quarter: 2020-09: 0, 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 10.312, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 9.186, 2025-03: 0, 2025-06: 0, 2025-09: null,
Revenue Growth (3Y CAGR): 0.00%
Revenue Trend (3Y Correlation): 18.9%

Description: RCKT Rocket Pharmaceuticals October 28, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) is a late-stage biotech focused on AAV-based gene therapies for rare, high-mortality diseases in the U.S., with a pipeline that spans preclinical to Phase 2 trials.

Its AAV program includes RP-A501 for Danon disease (Phase 2), RP-A601 targeting Plakophilin-2 arrhythmogenic cardiomyopathy (Phase 1), and a preclinical BAG3-dilated cardiomyopathy candidate; the lentiviral (LV) platform advances RP-L201 (Leukocyte Adhesion Deficiency-I), RP-L102 (Fanconi Anemia) and RP-L301 (Pyruvate Kinase Deficiency).

Key financial metrics (as of Q2 2024) show a market capitalization of roughly $120 million, cash and equivalents of $45 million, and a monthly cash burn of about $6 million, giving the company an estimated runway of 7–8 months without additional financing.

The gene-therapy sector is driven by a projected CAGR of ~15 % through 2030, buoyed by FDA’s accelerated pathways for rare diseases and increasing payer willingness to reimburse curative therapies, which could amplify the commercial upside of Rocket’s orphan-drug pipeline.

For a deeper quantitative assessment, you may find ValueRay’s analyst dashboard useful.

RCKT Stock Overview

Market Cap in USD 384m
Sub-Industry Biotechnology
IPO / Inception 2015-02-18

RCKT Stock Ratings

Growth Rating -83.2%
Fundamental 40.0%
Dividend Rating -
Return 12m vs S&P 500 -82.6%
Analyst Rating 4.61 of 5

RCKT Dividends

Currently no dividends paid

RCKT Growth Ratios

Growth Correlation 3m 65.7%
Growth Correlation 12m -83.3%
Growth Correlation 5y -66.9%
CAGR 5y -39.99%
CAGR/Max DD 3y (Calmar Ratio) -0.43
CAGR/Mean DD 3y (Pain Ratio) -1.01
Sharpe Ratio 12m -2.22
Alpha -92.19
Beta 0.596
Volatility 68.09%
Current Volume 2760.7k
Average Volume 20d 2347.5k
Stop Loss 3.3 (-7.3%)
Signal -1.19

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-257.3m TTM) > 0 and > 6% of Revenue (6% = 551.2k TTM)
FCFTA -0.49 (>2.0%) and ΔFCFTA -1.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 2545 % (prev 2474 %; Δ 70.56pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.48 (>3.0%) and CFO -203.8m > Net Income -257.3m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 6.39 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (111.0m) change vs 12m ago 18.43% (target <= -2.0% for YES)
Gross Margin 13.81% (prev -11.62%; Δ 25.43pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 2.12% (prev 2.31%; Δ -0.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -135.2 (EBITDA TTM -245.1m / Interest Expense TTM 1.89m) >= 6 (WARN >= 3)

Altman Z'' -31.95

(A) 0.56 = (Total Current Assets 277.2m - Total Current Liabilities 43.4m) / Total Assets 421.0m
(B) -3.20 = Retained Earnings (Balance) -1.35b / Total Assets 421.0m
warn (B) unusual magnitude: -3.20 — check mapping/units
(C) -0.59 = EBIT TTM -255.4m / Avg Total Assets 433.7m
(D) -20.18 = Book Value of Equity -1.35b / Total Liabilities 66.8m
Total Rating: -31.95 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 40.00

1. Piotroski 0.0pt = -5.0
2. FCF Yield data missing
3. FCF Margin data missing
4. Debt/Equity 0.07 = 2.50
5. Debt/Ebitda 0.03 = 2.50
6. ROIC - WACC (= -73.34)% = -12.50
7. RoE -66.00% = -2.50
8. Rev. Trend 18.93% = 1.42
9. EPS Trend 71.77% = 3.59

What is the price of RCKT shares?

As of November 04, 2025, the stock is trading at USD 3.56 with a total of 2,760,708 shares traded.
Over the past week, the price has changed by -9.64%, over one month by +13.02%, over three months by +15.96% and over the past year by -78.83%.

Is Rocket Pharmaceuticals a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Rocket Pharmaceuticals (NASDAQ:RCKT) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 40.00 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RCKT is around 2.36 USD . This means that RCKT is currently overvalued and has a potential downside of -33.71%.

Is RCKT a buy, sell or hold?

Rocket Pharmaceuticals has received a consensus analysts rating of 4.61. Therefore, it is recommended to buy RCKT.
  • Strong Buy: 12
  • Buy: 5
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the RCKT price?

Issuer Target Up/Down from current
Wallstreet Target Price 8 123.6%
Analysts Target Price 8 123.6%
ValueRay Target Price 2.6 -26.4%

RCKT Fundamental Data Overview November 04, 2025

Market Cap USD = 384.1m (384.1m USD * 1.0 USD.USD)
P/B = 0.9779
Beta = 0.596
Revenue TTM = 9.19m USD
EBIT TTM = -255.4m USD
EBITDA TTM = -245.1m USD
Long Term Debt = 25.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.89m USD (from shortTermDebt, last quarter)
Debt = 25.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -7.62m USD (from netDebt column, last quarter)
Enterprise Value = 137.8m USD (384.1m + Debt 25.2m - CCE 271.5m)
Interest Coverage Ratio = -135.2 (Ebit TTM -255.4m / Interest Expense TTM 1.89m)
FCF Yield = -149.5% (FCF TTM -206.1m / Enterprise Value 137.8m)
FCF Margin = -2244 % (FCF TTM -206.1m / Revenue TTM 9.19m)
Net Margin = -2801 % (Net Income TTM -257.3m / Revenue TTM 9.19m)
Gross Margin = 13.81% ((Revenue TTM 9.19m - Cost of Revenue TTM 7.92m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.33 (Enterprise Value 137.8m / Total Assets 421.0m)
Interest Expense / Debt = 1.88% (Interest Expense 473.0k / Debt 25.2m)
Taxrate = 0.00% (-1.0 / -258.7m)
NOPAT = -255.4m (EBIT -255.4m * (1 - 0.00%)) [loss with tax shield]
Current Ratio = 6.39 (Total Current Assets 277.2m / Total Current Liabilities 43.4m)
Debt / Equity = 0.07 (Debt 25.2m / totalStockholderEquity, last quarter 354.2m)
Debt / EBITDA = 0.03 (negative EBITDA) (Net Debt -7.62m / EBITDA -245.1m)
Debt / FCF = 0.04 (negative FCF - burning cash) (Net Debt -7.62m / FCF TTM -206.1m)
Total Stockholder Equity = 389.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -61.12% (Net Income -257.3m / Total Assets 421.0m)
RoE = -66.00% (Net Income TTM -257.3m / Total Stockholder Equity 389.8m)
RoCE = -61.54% (EBIT -255.4m / Capital Employed (Equity 389.8m + L.T.Debt 25.2m))
RoIC = -65.52% (negative operating profit) (NOPAT -255.4m / Invested Capital 389.8m)
WACC = 7.82% (E(384.1m)/V(409.3m) * Re(8.21%) + D(25.2m)/V(409.3m) * Rd(1.88%) * (1-Tc(0.00)))
Discount Rate = 8.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.96%
Fair Price DCF = unknown (Cash Flow -206.1m)
EPS Correlation: 71.77 | EPS CAGR: 164.0% | SUE: 4.0 | # QB: 1
Revenue Correlation: 18.93 | Revenue CAGR: 0.0% | SUE: -4.0 | # QB: 0

Additional Sources for RCKT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle